Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden.
Muto S, Ozaki Y, Yamaguchi H, Mine H, Takagi H, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Nanamiya H, Imai JI, Isogai T, Watanabe S, Suzuki H. Muto S, et al. Among authors: watanabe s, watanabe m. Oncol Lett. 2021 Mar;21(3):203. doi: 10.3892/ol.2021.12464. Epub 2021 Jan 12. Oncol Lett. 2021. PMID: 33574942 Free PMC article.
Brief report on similar mutational changes in neurofibromatosis type 2 gene in minute pulmonary meningothelial-like nodule and meningioma of the central nervous system.
Higuchi M, Watanabe M, Inoue T, Yamaura T, Suzuki T, Saito M, Niitsuma K, Endo K, Oshibe I, Soeta N, Saito T, Hojo H, Munakata M, Suzuki H. Higuchi M, et al. Among authors: watanabe m. Oncotarget. 2018 Nov 13;9(89):36012-36016. doi: 10.18632/oncotarget.26325. eCollection 2018 Nov 13. Oncotarget. 2018. PMID: 30542514 Free PMC article.
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.
Ozaki Y, Muto S, Takagi H, Watanabe M, Inoue T, Fukuhara M, Yamaura T, Okabe N, Matsumura Y, Hasegawa T, Ohsugi J, Hoshino M, Shio Y, Tanaka D, Nanamiya H, Imai JI, Isogai T, Watanabe S, Suzuki H. Ozaki Y, et al. Among authors: watanabe s, watanabe m. Cancer Immunol Immunother. 2020 Jan;69(1):127-134. doi: 10.1007/s00262-019-02446-1. Epub 2019 Dec 6. Cancer Immunol Immunother. 2020. PMID: 31807880 Free PMC article.
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T, Muto S, Mine H, Takagi H, Watanabe M, Ozaki Y, Inoue T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Suzuki H. Yamaura T, et al. Among authors: watanabe m. Oncol Lett. 2020 Jun;19(6):4169-4176. doi: 10.3892/ol.2020.11524. Epub 2020 Apr 8. Oncol Lett. 2020. PMID: 32391110 Free PMC article.
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
Takagi H, Zhao S, Muto S, Yokouchi H, Nishihara H, Harada T, Yamaguchi H, Mine H, Watanabe M, Ozaki Y, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Kanno R, Aoki M, Tan C, Shimoyama S, Yamazaki S, Kikuchi H, Sakakibara-Konishi J, Oizumi S, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Honjo O, Minami Y, Nishimura M, Dosaka-Akita H, Nakamura K, Inano A, Isobe H, Suzuki H. Takagi H, et al. Among authors: watanabe m. Lung Cancer. 2021 Mar;153:134-142. doi: 10.1016/j.lungcan.2021.01.014. Epub 2021 Jan 14. Lung Cancer. 2021. PMID: 33508526 Free article.
CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma.
Watanabe M, Higashi T, Ozeki K, Higashi AY, Sugimoto K, Mine H, Takagi H, Ozaki Y, Muto S, Okabe N, Matsumura Y, Hasegawa T, Shio Y, Suzuki H, Chiba H. Watanabe M, et al. Sci Rep. 2021 Jun 15;11(1):12554. doi: 10.1038/s41598-021-91464-0. Sci Rep. 2021. PMID: 34131154 Free PMC article.
A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, Ozaki Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Shio Y, Suzuki H. Matsumura Y, et al. Among authors: watanabe m. Thorac Cancer. 2021 Aug;12(15):2225-2228. doi: 10.1111/1759-7714.14058. Epub 2021 Jun 23. Thorac Cancer. 2021. PMID: 34159737 Free PMC article.
13,916 results
You have reached the last available page of results. Please see the User Guide for more information.